Brief: Tenax Therapeutics Phase 3 Level Trial Misses Primary Endpoint
10/08/2026 12:09
BRIEF-Tenax Therapeutics Phase 3 Level Trial Misses Primary Endpoint Aug 10 (Reuters) - Orion Oyj ORNBV.HE:
LICENSE PARTNER TENAX THERAPEUTICS' PHASE 3 LEVEL TRIAL DID NOT REACH ITS PRIMARY ENDPOINT
TRIAL WAS PHASE 3 LEVEL TRIAL OF ORAL LEVOSIMENDAN IN PULMONARY HYPERTENSION DUE TO HEART FAILURE WITH PRESERVED EJECTION FRACTION (PH-HFPEF)
TENAX TO REQUEST MEETING WITH U.S. FDA TO DISCUSS REVISIONS TO ONGOING REGISTRATIONAL DEVELOPMENT OF LEVOSIMENDAN FOR TREATMENT OF PH-HFPEF
Source text: ID:nGNE9LsMkT
Further company coverage: ORNBV.HE
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))